© 2021 BioShin Limited. All rights reserved.
Focus. Innovation. Growth. Culture.A Differentiated Biotech
May 2021
Established in 2018 to advance treatment options for neurology and neuro-immune disorders for patients in the Asia-Pacific region
Vision: to become the leading neuroscience biotech in the region
COMMERCIAL-STAGE LEAD ASSET • DEEP PIPELINE • INTERNATIONAL MANAGEMENT AND INVESTORS
Corporate HeadquartersPudong, Shanghai
Hong Kong biotech sector booms on buoyant markets and pandemic
Telemedicine, elderly care services, and mental health were highlighted above other areas, and these segments are likely to see rapid development in the next five years.
China’s Healthcare Revolution
MAY 2021BIOSHIN INVESTOR PRESENTATION3
China Joins ICH as Full Regulatory Member, Pledges to Implement Guidelines
China has officially released its first national list of rare diseases
Many of China’s reforms aim to streamline the regulatory processes and improve access and reimbursement to encourage developers to enter China’s healthcare market.
Coming from the Chinese words “biao” (标) and “xin”(新), which form a
phrase meaning “unique” and “at the forefront”
BioShin embodies “new” and “innovative”
BioShin: A Forward-Looking Biotech
MAY 20214
FOCUS
Build a leading biotech with the singular focus on the needs of the rapidly growing healthcare industry and patients in China and Asia
INNOVATE
Become the go-to partner for US and ex-China biotechs seeking to optimize the value of their innovative assets in the greater China and Asia healthcare markets
PURPOSE
Create value for patients and society by investing in novel, differentiated medicines to address unmet need
CULTURE
Focus on bringing together exceptional talent committed to integrity and an innovative mindset
标新
BIOSHIN INVESTOR PRESENTATION
Leadership: Deep Global and China Experience
MAY 20215
Sarah Lu MD *CHIEF MEDICAL OFFICER
David ChungCHIEF STRATEGY OFFICER
Donnie McGrath, MD MPHPRESIDENT AND EXECUTIVE CHAIRMAN
Karl Lintel, MD CHIEF EXECUTIVE OFFICER
Zoey (Zhiyao) Wang, MD MPAGENERAL MANAGER
Jonny Zhang, CPA, CFA VP FINANCE
Matthew Tan, MD VP MEDICAL
Sandy LiangHEAD OF REGULATORY AFFAIRS
Elaine HawkingsHEAD OF CLINICAL OPERATIONS
Helen ZhangSR DIRECTOR CLINICAL OPERATIONS
P R I O R P R O F E S S I O N A L R O L E S
BIOSHIN INVESTOR PRESENTATION
S E L E C T D E V E L O P M E N T E X P E R I E N C E
Mary Li Ma*CHIEF COMMERCIAL OFFICER
* Starting June 1st 2021
Growth Strategy:Reaching New Horizons with Multiple Approaches
APRIL 2021DRAFT. CONFIDENTIAL.6
Through a deep clinical
pipeline, partnerships
and discovery, BioShin
will address unmet need
in Asia-Pacific and
deliver growthLAUNCHING INNOVATIVE TREATMENTS for migraine, rare diseases, neurological disorders, and CGRP-mediated diseases
PARTNERING INNOVATION - ensure the best assets to address patient needs are brought to China and Asia-Pacific region
DISCOVERY INNOVATION -developing novel assets
Leading China-based
biotech
BIOSHIN INVESTOR PRESENTATION
Migraine in China
~90 Million People with Migraine in China2
• No innovation in over 20 years• No multinational corporate
investment in innovative medication
• NMPA: “acute treatment of migraine is an unmet medical need condition”3
Migraine: Significant Unmet Need with Limited Competition
1. http://www.ihs-headache.org/binary_data/3349_ichd-3-chinese.pdf2. Yu, S., et al., The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache, 2012. 52(4): p. 582-913. NMPA rimegepant pre-IND minutes
8
• 100% of migraine patients with/without aura1 need acutetherapy
• Rimegepant will be first oral CGRP-targeting small molecule therapy for acute treatment
• Uniquely positioned – uniqueprofile with dual indication
ACUTE TREATMENT OPPORTUNITY CURRENT PRE-CGRP LANDSCAPE
BIOSHIN INVESTOR PRESENTATION MAY 2021
Nonresponders Cannot tolerate Recurrence Cardiovascular Contraindications
Medication Overuse Headache (MOH)
Up to 55% of people do not have sufficient relief with
currently available treatments1
43% experience AEs within 24 hours2
17% to 40% experience return of migraine
pain/symptoms within 24 hours3
Approximately 2.6M in the US4
Overuse of many current acute therapies can
cause MOH5
Oral CGRP-receptor Antagonists AddressDrawbacks of Current SOC Treatments*
References: 1. Lipton RB et al. Headache. 2017;57(7):1026-1040. 2. Derry CJ et al. Cochrane Database Syst Rev. 2012;2(2):CD008615. 3. Géraud G et al. Headache. 2003;43(4):376-388. 4. Buse DC et al. Headache. 2017;57(1):31-44. 5. Schwedt TJ et al. J Headache Pain. 2018;19(1):38. *Quote: NMPA
9
BioShin is positioned to select and adapt best practices from the successful initial launch to the China market
BIOSHIN INVESTOR PRESENTATION MAY 2021
At the Forefront of the Healthcare Revolution